Long-Term Outcomes of Myeloid Growth Factor Treatment

Restricted access

Myeloid growth factors are used to reduce myelotoxicity and the risk of infection after cancer chemotherapy and in patients with chronic neutropenia. This article addresses the long-term benefits and risks associated with granulocyte colony-stimulating factor (G-CSF) therapy in both settings. A systematic review of randomized controlled trials recently reported long-term outcomes regarding the risk of second malignancies and overall survival. Based on these studies, the risk for acute myeloid leukemia (AML) associated with known carcinogenic agents, such as chemotherapy, could not be distinguished from any risk associated with growth factor support. However, the enhanced delivery of chemotherapy dose intensity enabled by the use of G-CSF in these studies was associated with a significant reduction in all-cause mortality. Although some reduction in treatment-related mortality with G-CSF support may occur, the observed improvement in long-term survival likely relates to better disease control with more-intense G-CSF–supported chemotherapy. Myeloid growth factors have also been shown to benefit patients with severe chronic neutropenia. Almost all patients with cyclic, congenital, or idiopathic neutropenia experience response to G-CSFs. Treatment is titrated to determine a dose that provides a safe elevation in neutrophil counts. Reports have shown that patients can be maintained for years at the same dose after adjusting for growth and development. In congenital neutropenia, the inherent risk of developing myelodysplastic syndromes or AML requires careful monitoring, including routine blood counts and annual bone marrow examinations.

Correspondence: Gary H. Lyman, MD, MPH, Duke University Medical Center and the Duke Cancer Institute, 2424 Erwin Road, Suite 205, Durham, NC 27705. E-mail: Gary.Lyman@Duke.edu
  • 1

    KudererNMDaleDCCrawfordJ. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol2007;25:31583167.

    • Search Google Scholar
    • Export Citation
  • 2

    WittmanBHoranJLymanGH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev2006;32:289303.

    • Search Google Scholar
    • Export Citation
  • 3

    AaproMSBohliusJCameronDA. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer2011;47:832.

    • Search Google Scholar
    • Export Citation
  • 4

    CrawfordJArmitageJBalducciL. NCCN Clinical Practice Guidelines in Oncology for Myeloid Growth Factors. J Natl Compr Canc Netw2009;7:6483.

    • Search Google Scholar
    • Export Citation
  • 5

    SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol2006;24:31873205.

    • Search Google Scholar
    • Export Citation
  • 6

    CastroGAChurchAPechetL. Leukemia after chemotherapy of Hodgkin's disease. N Engl J Med1973;289:103104.

  • 7

    PreislerHDLymanGH. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. Am J Hematol1977;3:209218.

    • Search Google Scholar
    • Export Citation
  • 8

    CrumpMTuDShepherdL. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2003;21:30663071.

    • Search Google Scholar
    • Export Citation
  • 9

    KalaycioMRybickiLPohlmanB. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol2006;24:36043610.

    • Search Google Scholar
    • Export Citation
  • 10

    Le DeleyMCSuzanFCutuliB. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol2007;25:292300.

    • Search Google Scholar
    • Export Citation
  • 11

    LeoneGPaganoLBen-YehudaD. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica2007;92:13891398.

  • 12

    PattDADuanZFangS. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol2007;25:38713876.

    • Search Google Scholar
    • Export Citation
  • 13

    PragaCBerghJBlissJ. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol2005; 23:41794191.

    • Search Google Scholar
    • Export Citation
  • 14

    HershmanDNeugutAIJacobsonJS. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst2007;99:196205.

    • Search Google Scholar
    • Export Citation
  • 15

    RellingMVBoyettJMBlancoJG. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood2003;101:38623867.

    • Search Google Scholar
    • Export Citation
  • 16

    LymanGHDaleDCWolffDA. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol2010;28:29142924.

    • Search Google Scholar
    • Export Citation
  • 17

    ClarkOALymanGHCastroAA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol2005;23:41984214.

    • Search Google Scholar
    • Export Citation
  • 18

    DaleDCGuerryDWerwerkaJR. Chronic neutropenia. Medicine1979;58:128144.

  • 19

    WelteKZeidlerC. Severe congenital neutropenia. Hematol Oncol Clin North Am2009;23:307320.

  • 20

    BoxerLDaleDC. Neutropenia: causes and consequences. Semin Hematol2002;39:7581.

  • 21

    DaleDCHammondWP. Cyclic neutropenia: a clinical review. Blood Rev1988;2:178185.

  • 22

    HorwitzMBensonKFPersonRE. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genetics1999;23:433436.

    • Search Google Scholar
    • Export Citation
  • 23

    DaleDCPersonREBolyardAA. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood2000;96:23172322.

    • Search Google Scholar
    • Export Citation
  • 24

    KleinCGrudzienMAppaswamyG. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet2007;39:8692.

    • Search Google Scholar
    • Export Citation
  • 25

    DaleDCLinkDC. The many causes of severe congenital neutropenia. N Engl J Med2009;360:35.

  • 26

    PapadakiHAPontikoglouC. Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Expert Rev Hematol2008;12:217229.

    • Search Google Scholar
    • Export Citation
  • 27

    JakubowskiAASouzaLKellyF. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med1989;320:3842.

    • Search Google Scholar
    • Export Citation
  • 28

    HammondWPPriceTHSouzaLMDaleDC. Treatment of cyclic neutropenia with granulocyte colony stimulating factor. N Engl J Med1989;320:13061311.

    • Search Google Scholar
    • Export Citation
  • 29

    BonillaMAGillioAPRuggeiroM. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med1989;320:15741580.

    • Search Google Scholar
    • Export Citation
  • 30

    WelteKZeidlerCReiterA. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood1990;75:10561063.

    • Search Google Scholar
    • Export Citation
  • 31

    ImashukuSTsuchidaMSasakiM. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with chronic benign granulocytopenia and congenital agranulocytosis (Kostmann's syndrome). Acta Paediatr1992;81:133136.

    • Search Google Scholar
    • Export Citation
  • 32

    DaleDCBonillaMADavisMW. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood1993;81:24962502.

    • Search Google Scholar
    • Export Citation
  • 33

    DaleDCCottleTEFierCJ. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol2003;72:8293.

    • Search Google Scholar
    • Export Citation
  • 34

    DaleDCBolyardAASchwinzerBG. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther2006;3:220231.

    • Search Google Scholar
    • Export Citation
  • 35

    WrightDGKenneyRFOetteDH. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. Blood1994;84:12571267.

    • Search Google Scholar
    • Export Citation
  • 36

    MoriPGPasinoMDufourC. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and rhG-CSF in the treatment of a child with severe chronic neutropenia. Blood1994;84:32443245.

    • Search Google Scholar
    • Export Citation
  • 37

    JonesEBolyardAADaleDC. Quality of life in patients receiving granulocyte colony stimulating factor for treatment of severe chronic neutropenia. JAMA1993;270:11321133.

    • Search Google Scholar
    • Export Citation
  • 38

    RosenbergPSAlterBPBolyardAA. Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood2006;107:46284635.

    • Search Google Scholar
    • Export Citation
  • 39

    RosenbergPSZeidlerCBolyardAA. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol2010;150:196199.

    • Search Google Scholar
    • Export Citation
  • 40

    RosenbergPSAlterBPLinkDC. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol2008;140:210213.

    • Search Google Scholar
    • Export Citation
  • 41

    DiMeglioLABolyardAAMarreroTM. The risk of low bone mineral density with long-term G-CSF therapy for severe chronic neutropenia [abstract]. Blood2010;16:Abstract 634.

    • Search Google Scholar
    • Export Citation
  • 42

    BoxerLABolyardAAMarreroTM. Outcomes of pregnancies for women with severe chronic neutropenia with or without G-CSF treatment [abstract]. Blood2010;16:635636.

    • Search Google Scholar
    • Export Citation
  • 43

    ChoiSWBoxerLAPulsipherMA. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant2005;35:473477.

    • Search Google Scholar
    • Export Citation
  • 44

    CarlssonGWiniarskiJLjungmanP. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer2011;56:444451.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 43 43 3
PDF Downloads 15 15 1
EPUB Downloads 0 0 0